Company intelligence / Profile preview

Innovate Biopharmaceuticals

Raleigh, North Carolina, United Statesinnovatebiopharma.com ↗

Ownership: Private
Development stage: Other

Overview

Larazotide acetate (INN‑202) met its primary endpoint in a phase 2b trial for celiac disease, showing reduction of clinical symptoms and favorable safety profile. It received FDA Fast Track designation and advanced to phase 3 trials. INN‑108 entered phase 2 trials for mild-to-moderate ulcerative colitis, designed as a colon-targeted prodrug with local anti-inflammatory effects. Other pipeline assets included early-stage programs for NASH and Crohn’s.

Therapeutic areas: Gastroenterology
Modalities: PeptidesSmall molecule
Industry: Biotech

Drug pipeline

16 assets

vurolenatide

15 more assets in the full pipeline.

Request access →

Partnerships

Research collaboration with Massachusetts General Hospital on alcoholic steatohepatitis therapy development

Beyond the preview

Go deeper on Innovate Biopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innovate Biopharmaceuticals.

Explore the full profile